NVCR News and Press, NovoCure Limited From 09/27/22

Summary NovoCure faces a host of growth options along two key vectors: new geographies and other cancer applications. Despite short-term de-growth in active patients, long-term tailwinds to market share justify the company's superior multiple expansion. A conservative valuatio...

Oncology company Novocure ( NASDAQ: NVCR ) on Wednesday announced the creation of a central nervous system focused cancers franchise. NVCR's chief development officer Frank Leonard was named president of the new organization, U.S. CNS Cancers Franchise. The franchise w...

Frank Leonard is appointed President, CNS Cancers U.S. Novocure (NASDAQ: NVCR) today announced the creation of its U.S. CNS (central nervous system) Cancers Franchise. This new organization will add resources, streamline decision-making and improve coordination across Novocu...

Summary NovoCure has maintained a large amount of institutional investors since IPO in 2015, and has nearly 78% of shares held by institutions today. Insider Ownership is high as well at 14% indicating employees have conviction in the long-term outlook of the company. NovoCure...

Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Executive Chairman, and Ashley Cordova, Chief Financial Officer, will participate in the 2022 Wells Fargo Healthcare Conference on September 7, 2022. Mr. Doyle a...

Brian Orelli, biotech contributor and writer at The Motley Fool, joins the channel to discuss why he owns Novocure (NASDAQ: NVCR) stock. Check out his reasoning in this video! *Stock prices used were the midday prices of Aug. 10, 2022. The video was published on Aug. 21, 2022....

Most investors like the idea of getting in early on an up-and-coming stock. But doing so isn't always easy. Sometimes what seems to be a rising star can crash and burn. We asked three Motley Fool contributors to pick monster stocks in the making to buy right now. Here's why they chose ...

After posting the worst first half of any year since 1970 (1), the stock market has come roaring back to life in Q3, with technology and risk bets leading the way following Fed Chair Jerome Powell’s signal at the July FOMC meeting of a possible shift in policy bearing. (2) The Fed beli...

Sen. Hassan toured the company’s U.S. headquarters in Portsmouth before meeting and speaking with employees On Tuesday, Aug. 9, U.S. Sen. Maggie Hassan (NH) joined members of Novocure’s leadership team to tour the company’s U.S. headquarters in Portsmout...

Baillie Gifford’s 13F portfolio value decreased from ~$143B to ~$97.51B this quarter. They increased Spotify and Royalty Pharma while decreasing Cloudflare, Petrobras, BeiGene, CBRE Group, Teladoc, and Peloton Interactive. The top three positions are Moderna, Tesla Motors, ...